REal World MAIA UK OutcomEs
NCT07532473 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2026-04-20
Summary
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
The Royal Wolverhampton Hospitals NHS Trust
lead OTHER_GOV
Principal Investigators
-
Hannah Giles · University Hospital Birmingham NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-31
- Primary Completion
- 2028-07-31
- Completion
- 2028-07-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
NCT01237249 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
NCT00305812 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
NCT03481556 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma
NCT02537808 ·Status: COMPLETED
-
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT04113018 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
NCT01861340 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
NCT01936532 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NCT00843310 ·Status: TERMINATED ·Phase: PHASE2
-
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
NCT04288765 ·Status: WITHDRAWN ·Phase: PHASE3
-
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
NCT00907452 ·Status: COMPLETED ·Phase: NA
-
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
NCT01615029 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
NCT02874742 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
NCT00603447 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT03234972 ·Status: COMPLETED ·Phase: PHASE3
-
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT03361306 ·Status: COMPLETED ·Phase: PHASE2
-
Myeloma Novel Drug Discovery Ver 1.2
NCT05968417 ·Status: RECRUITING
-
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
NCT03104842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
NCT00378105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
NCT04892264 ·Status: TERMINATED ·Phase: PHASE1
-
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
NCT03710603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
NCT01080391 ·Status: COMPLETED ·Phase: PHASE3